Here, we present evidence that Tpl2 is overexpressed in our CML cellular model of resistance to imatinib mesylate (IM) and that MAP3K8, together with NFKB1 transcript levels, are significantly elevated in CML CD34+ cells exposed to IM. The gene discussed is NFKB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.